Alnylam Pharmaceuticals (ALNY) Net Cash Flow (2009 - 2026)

Alnylam Pharmaceuticals' Net Cash Flow history runs 18 years deep, the most recent figure standing at $60.7 million for Q1 2026.

• Quarterly Net Cash Flow rose 53.46% year-over-year to $60.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $676.4 million (up 105.72% YoY) and the FY2025 annual result came in at $655.2 million, up 287.69% from the prior year.
• Net Cash Flow was $60.7 million for Q1 2026 at Alnylam Pharmaceuticals, down from $171.7 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $495.6 million in Q3 2022 and bottomed at -$283.7 million in Q1 2022.
• A 5-year average of $51.7 million and a median of $50.3 million in 2022 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow sank 150.73% — and 2024, when it surged 2124.43%.
• Alnylam Pharmaceuticals' Net Cash Flow stood at -$208.5 million in 2022, then retreated by 10.92% to -$231.2 million in 2023, then surged by 49.58% to -$116.6 million in 2024, then jumped by 247.29% to $171.7 million in 2025, then slumped by 64.66% to $60.7 million in 2026.
• Business Quant data shows ALNY's Net Cash Flow at $60.7 million in Q1 2026, $171.7 million in Q4 2025, and $377.9 million in Q3 2025.